Claudin18.2 (CLDN18.2) is a splice variant of the membrane epithelial tight junctions protein Claudin18 (CLDN18) and has been identified as a promising biomarker for targeted therapy. While upon malignant transformation, the changes in cell polarity lead to the exposure of CLDN18.2 epitopes. which are suitable for targeted therapy. Prior evidence demonstrates that except for GC, CLDN18.2 is aberrantly expressed in various primary tumors and metastases, including pancreatic, biliary, ovarian, and lung adenocarcinomas, which makes CLDN18.2 a pan-cancer target.
Specifications
Catalog No.
BX50272
Clone No.
BP6249
Application
IHC-P
Subcellular location
Membrane
Control
Stomach
Recommended method
HIER
Volume
100μl/vial, 1ml/vial
Dilution
1:100-1:200
Immunogen
Recombinant protein fragment of human Claudin18.2 was used as an immunogen.
Reference
1. Xu B et al. J Gastrointest Oncol 11:1431-1439 (2020).
2. Moentenich V et al. Oncol Lett 19:3665-3670 (2020).